Drugs Made In America Acquisition Corp- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Drugs Made In America Acquisition Corp 公司

Drugs Made In America Acquisition Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. The Company intends to focus its search for businesses in the pharmaceutical industry. The Company has neither engaged in any operations nor generated any revenues.

Drugs Made In America Acquisition Corp简介



公司代码DMAA

公司名称Drugs Made In America Acquisition Corp

上市日期Jan 28, 2025

CEOStockwell (Lynn)

员工数量- -

证券类型Ordinary Share

年结日Jan 28

公司地址1 East Broward Boulevard

城市FT LAUDERDALE

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编33301

电话19548703099

网址

公司代码DMAA

上市日期Jan 28, 2025

CEOStockwell (Lynn)

Drugs Made In America Acquisition Corp公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Catherine Do

Independent Director Nominee

100.00K

--

Ms. Lynn Stockwell

Executive Chairman of the Board, Chief Executive Officer

--

Dr. G. Sridhar Prasad

Independent Director Nominee

--

Mr. Myron W. Shulgan

Independent Director Nominee

--

Mr. Saleem Elmasri, CPA

Chief Financial Officer, Principal Financial and Accounting Officer

--

名称

名称/职务

职务

持股

持股变动

Dr. Catherine Do

Independent Director Nominee

100.00K

--

Ms. Lynn Stockwell

Executive Chairman of the Board, Chief Executive Officer

--

Dr. G. Sridhar Prasad

Independent Director Nominee

--

Mr. Myron W. Shulgan

Independent Director Nominee

--

Mr. Saleem Elmasri, CPA

Chief Financial Officer, Principal Financial and Accounting Officer

--

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月17日周一

持股股东

股东类型

持股股东

占比

Drugs Made In America Acquisition LLC

25.57%

Karpus Investment Management

7.60%

First Trust Capital Management L.P.

6.69%

Polar Asset Management Partners Inc.

5.67%

Glazer Capital, LLC

5.44%

其他

49.03%

持股股东

占比

Drugs Made In America Acquisition LLC

25.57%

Karpus Investment Management

7.60%

First Trust Capital Management L.P.

6.69%

Polar Asset Management Partners Inc.

5.67%

Glazer Capital, LLC

5.44%

其他

49.03%

股东类型

持股股东

占比

Hedge Fund

30.42%

Corporation

25.57%

Investment Advisor/Hedge Fund

24.61%

Investment Advisor

5.80%

Research Firm

5.62%

Individual Investor

1.19%

其他

6.79%

机构持股



更新时间: 12月8日周一

报告期

机构数

持股数

持股占比

持股变动

2025Q4

48

22.27M

66.45%

-743.43K

2025Q3

47

22.22M

67.76%

+1.02M

2025Q2

38

21.21M

54.90%

+2.81M

2025Q1

25

18.33M

0.00%

+18.33M

2024Q4

5

4.59M

15.73%

+4.59M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Drugs Made In America Acquisition LLC

8.57M

25.57%

+4.38M

+104.63%

Feb 25, 2025

Karpus Investment Management

2.55M

7.6%

-196.44K

-7.16%

Sep 30, 2025

First Trust Capital Management L.P.

2.24M

6.69%

--

Sep 30, 2025

Polar Asset Management Partners Inc.

1.90M

5.67%

--

Sep 30, 2025

Glazer Capital, LLC

1.82M

5.44%

-158.00

-0.01%

Sep 30, 2025

Westchester Capital Management, LLC

1.67M

4.98%

--

Sep 30, 2025

Hudson Bay Capital Management LP

1.55M

4.62%

-250.00K

-13.89%

Sep 30, 2025

Wolverine Asset Management, LLC

1.25M

3.73%

+227.22K

+22.24%

Sep 30, 2025

Mizuho Securities USA, LLC.

1.10M

3.28%

+180.66K

+19.64%

Sep 30, 2025

Aristeia Capital, L.L.C.

881.72K

2.63%

--

Sep 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

CrossingBridge Pre-Merger SPAC ETF

0%

CrossingBridge Pre-Merger SPAC ETF

占比0%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

除权除息日

类型

比率

暂无数据

公告日期

除权除息日

类型

比率

暂无数据